Location of Repository

Mycobacterium tuberculosis thymidylate synthase gene thyX is essential and potentially bifunctional, while thyA deletion confers resistance to p-aminosalicylic acid

By Amanda S. Fivian-Hughes, Joanna Houghton and Elaine O. Davis

Abstract

Thymidylate synthase (TS) enzymes catalyse the biosynthesis of deoxythymidine monophosphate (dTMP or thymidylate), and so are important for DNA replication and repair. Two different types of TS proteins have been described (ThyA and ThyX), which have different enzymic mechanisms and unrelated structures. Mycobacteria are unusual as they encode both thyA and thyX, and the biological significance of this is not yet understood. Mycobacterium tuberculosis ThyX is thought to be essential and a potential drug target. We therefore analysed M. tuberculosis thyA and thyX expression levels, their essentiality and roles in pathogenesis. We show that both thyA and thyX are expressed in vitro, and that this expression significantly increased within murine macrophages. Under all conditions tested, thyA expression exceeded that of thyX. Mutational studies show that M. tuberculosis thyX is essential, confirming that the enzyme is a plausible drug target. The requirement for M. tuberculosis thyX in the presence of thyA implies that the essential function of ThyX is something other than dTMP synthase. We successfully deleted thyA from the M. tuberculosis genome, and this deletion conferred an in vitro growth defect that was not observed in vivo. Presumably ThyX performs TS activity within M. tuberculosis ΔthyA at a sufficient rate in vivo for normal growth, but the rate in vitro is less than optimal. We also demonstrate that thyA deletion confers M. tuberculosis p-aminosalicylic acid resistance, and show by complementation studies that ThyA T202A and V261G appear to be functional and non-functional, respectively

Topics: Cell and Molecular Biology of Microbes
Publisher: Society for General Microbiology
OAI identifier: oai:pubmedcentral.nih.gov:3352284
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Preview

    Citations

    1. (2007). [Mutations in the thymidylate synthase gene is a major mechanism in the paraaminosalicylic acid resistance of M. tuberculosis]. Zhonghua Jie He He Hu Xi Za Zhi 30, 683–685 (in Chinese).
    2. (2005). A member of the cAMP receptor protein family of transcription regulators in Mycobacterium tuberculosis is required for virulence in mice and controls transcription of the rpfA gene coding for a resuscitation promoting factor.
    3. (2010). Activity-based metabolomic profiling of enzymatic function: identification of Rv1248c as a mycobacterial 2-hydroxy-3-oxoadipate synthase.
    4. (2010). Alternative thymidylate synthase, ThyX, involved in Corynebacterium glutamicum ATCC 13032 survival during stationary growth phase.
    5. (2007). An adaptation of the LMS method to determine expression variations in profiling data.
    6. (2002). An alternative flavin-dependent mechanism for thymidylate synthesis.
    7. (2009). An unusual mechanism of thymidylate biosynthesis in organisms containing the thyX gene.
    8. (2010). Analyzing the regulatory role of the HigA antitoxin within Mycobacterium tuberculosis.
    9. Antimicrob Agents Chemother 53, 2100–2109. thyX is essential and DthyA is PAS-resistant http://mic.sgmjournals.org 317Myllykallio,
    10. (2010). Biochemical characterization of two thymidylate synthases in Corynebacterium glutamicum NCHU 87078.
    11. (1999). Cloning and expression of Mycobacterium tuberculosis and Mycobacterium leprae dihydropteroate synthase in Escherichia coli.
    12. (2010). Development of a repressible mycobacterial promoter system based on two transcriptional repressors.
    13. (2005). Direct observation of the participation of flavin in product formation by thyX-encoded thymidylate synthase.
    14. (2003). Efficient switching of mycobacteriophage L5-based integrating plasmids in Mycobacterium tuberculosis.
    15. (2010). Extensively drug-resistant tuberculosis: A sign of the times and an impetus for antimicrobial discovery. Pharmaceuticals (Basel)
    16. (2007). Flavin-dependent thymidylate synthase ThyX activity: implications for the folate cycle in bacteria.
    17. (2011). Forkheadassociated (FHA) domain containing ABC transporter Rv1747 is positively regulated by Ser/Thr phosphorylation in Mycobacterium tuberculosis.
    18. (2008). Functional analysis of the Mycobacterium tuberculosis FADdependent thymidylate synthase, ThyX, reveals new amino acid residues contributing to an extended ThyX motif.
    19. (2003). Genes required for mycobacterial growth defined by high density mutagenesis.
    20. (2002). Genetic evidence for a novel thymidylate synthase in the halophilic archaeon Halobacterium salinarum and in Campylobacter jejuni.
    21. (2004). Genomics of Mycobacterium tuberculosis: old threats & new trends.
    22. (2006). Global incidence of multidrug-resistant tuberculosis.
    23. (2008). Global transcriptional profile of Mycobacterium tuberculosis during THP-1 human macrophage infection.
    24. (2009). Global tuberculosis control: epidemiology, strategy, financing.
    25. (2001). Instability and site-specific excision of integrationproficient mycobacteriophage L5 plasmids: development of stably maintained integrative vectors.
    26. (1998). Intracellular gene expression: analysis of RNA from mycobacteria in macrophages using RT-PCR.
    27. (2008). Kinetics and ligand-binding preferences of Mycobacterium tuberculosis thymidylate synthases, ThyA and ThyX.
    28. (2003). Life without dihydrofolate reductase FolA.
    29. (2004). Mechanistic studies of a flavin-dependent thymidylate synthase.
    30. (2006). NADP + expels both the co-factor and a substrate analog from the Mycobacterium tuberculosis ThyX active site: opportunities for antibacterial drug design.
    31. other authors (2002). Crystal structure of Thy1, a thymidylate synthase complementing protein from Thermotoga maritima at 2.25 A ˚ resolution.
    32. other authors (2003). Transcriptional adaptation of Mycobacterium tuberculosis within macrophages: insights into the phagosomal environment.
    33. other authors (2009). Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis.
    34. other authors (2011). Synthesis and evaluation of 5-substituted 29-deoxyuridine monophosphate analogues as inhibitors of flavindependent thymidylate synthase in Mycobacterium tuberculosis.
    35. other authors (2011). The biological and structural characterization of Mycobacterium tuberculosis UvrA provides novel insights into its mechanism of action.
    36. (2007). Silencing Mycobacterium smegmatis by using tetracycline repressors.
    37. (2005). Structure of the Mycobacterium tuberculosis flavin dependent thymidylate synthase (MtbThyX) at 2.0 A ˚ resolution.
    38. (1995). The catalytic mechanism and structure of thymidylate synthase.
    39. (2011). The challenge of new drug discovery for tuberculosis.
    40. (2004). The folate pathway is a target for resistance to the drug para-aminosalicylic acid (PAS) in mycobacteria.
    41. (2004). The temporal expression profile of Mycobacterium tuberculosis infection in mice.
    42. (2002). The use and analysis of microarray data.
    43. (2010). Thr202Ala in thyA is a marker for the Latin American Mediterranean lineage of the Mycobacterium tuberculosis complex rather than para-aminosalicylic acid resistance.
    44. (2002). Transcription of the Mycobacterium tuberculosis recA gene.
    45. (2000). Use of a flexible cassette method to generate a double unmarked Mycobacterium tuberculosis tlyA plcABC mutant by gene replacement.
    46. (2005). Use of a tetracycline-inducible system for conditional expression in Mycobacterium tuberculosis and Mycobacterium smegmatis.
    47. (2010). Usefulness of resistant gene markers for predicting treatment outcome on second-line anti-tuberculosis drugs.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.